A case of ustekinumab-induced sclerouveitis.
A case of ustekinumab-induced sclerouveitis.
- 2022
Conclusions: To the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition. Copyright (c) 2022 The Authors. Observations: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis. Purpose: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-alpha inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics.
English
10.1016/j.ajoc.2022.101331 [doi] PMC8819278 [pmc] S2451-9936(22)00077-9 [pii]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Ophthalmology Residency
Case Reports
Conclusions: To the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition. Copyright (c) 2022 The Authors. Observations: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis. Purpose: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-alpha inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics.
English
10.1016/j.ajoc.2022.101331 [doi] PMC8819278 [pmc] S2451-9936(22)00077-9 [pii]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Ophthalmology Residency
Case Reports